Skip to main content

Advertisement

SpringerLink
Log in

Antiosteoporotic Drugs and Incidence of Type 2 Diabetes Mellitus

  • Letter to the Editor
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Vestergaard P (2011) Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate. Calcif Tissue Int 89:265–270

    Article  PubMed  CAS  Google Scholar 

  2. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469

    Article  PubMed  CAS  Google Scholar 

  3. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Ducy P, Karsenty G (2010) Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell 142:296–308

    Article  PubMed  CAS  Google Scholar 

  4. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:45–49

    Article  PubMed  CAS  Google Scholar 

  5. Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 26:260–264

    Article  PubMed  CAS  Google Scholar 

  6. Luckish A, Cernes R, Boaz M, Gavish D, Matas Z, Fux A, Shargorodsky M (2008) Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors. Bone 43:279–283

    Article  PubMed  CAS  Google Scholar 

  7. Celiloglu M, Aydin Y, Balci P, Kolamaz T (2009) The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689–693

    Article  PubMed  Google Scholar 

  8. Majima T, Komatsu Y, Shimatsu A, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K (2007) Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis. Endocr J 54:855–862

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine 1, Shimane University Faculty of Medicine, Shimane, Japan

    Ippei Kanazawa

Authors
  1. Ippei Kanazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ippei Kanazawa.

Additional information

The author has stated that there is no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanazawa, I. Antiosteoporotic Drugs and Incidence of Type 2 Diabetes Mellitus. Calcif Tissue Int 90, 163–164 (2012). https://doi.org/10.1007/s00223-011-9555-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00223-011-9555-4

Keywords

Search

Navigation